In response to the 2014-2016 Ebola epidemic, the clinical development of a two-dose regimen of vaccines Ad26.ZEBOV and MVA-BN-Filo was accelerated. Approved in 2020 by the European Commission for use in epidemic emergencies, this regimen continues to demonstrate its relevance. An Inserm study led by Rodolphe Thiébaut (Inserm, INRIA, Université de Bordeaux, Vaccine Research Institute) has played a role in evaluating its safety and immunogenicity in healthy adults and in those with HIV and compared different time intervals between the two doses. It has confirmed that this regimen is well tolerated, that the antibodies acquired persist for at least one year, and that they can be easily reactivated by a booster shot. The findings of this trial have been published in Plos Medicine.

 

The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission Approval for Janssen's Ebola vaccine regimen.

Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen developed in partnership with Bavarian Nordic for the prevention of Ebola Virus Disease. The full press release can be found HERE.

Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen. The full press release can be found here

Page 1 of 7

NEWS

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings

×

Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as NotAllowedScriptReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions